ASCENTAGE PHARMA GROUP INTERNATIONAL
AAPG · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $234 | $157 | $824 | $79 |
| % Growth | 48.9% | -81% | 939% | – |
| Cost of Goods Sold | $22 | $14 | $15 | $12 |
| Gross Profit | $212 | $143 | $809 | $67 |
| % Margin | 90.7% | 91.1% | 98.2% | 84.4% |
| R&D Expenses | $529 | $503 | $444 | $397 |
| G&A Expenses | $100 | $100 | $87 | $90 |
| SG&A Expenses | $237 | $206 | $177 | $202 |
| Sales & Mktg Exp. | $138 | $106 | $90 | $112 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $766 | $710 | $621 | $599 |
| Operating Income | -$554 | -$567 | $188 | -$532 |
| % Margin | -237.1% | -361.2% | 22.8% | -671.1% |
| Other Income/Exp. Net | -$31 | $9 | -$25 | -$1 |
| Pre-Tax Income | -$585 | -$558 | $163 | -$533 |
| Tax Expense | $6 | $10 | $0 | -$10 |
| Net Income | -$591 | -$568 | $163 | -$523 |
| % Margin | -252.8% | -362.3% | 19.8% | -660% |
| EPS | -1.73 | -1.82 | 0.56 | -1.8 |
| % Growth | 4.9% | -425% | 131.1% | – |
| EPS Diluted | -1.73 | -1.82 | 0.55 | -1.8 |
| Weighted Avg Shares Out | 341 | 312 | 296 | 290 |
| Weighted Avg Shares Out Dil | 342 | 312 | 296 | 290 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $28 | $20 |
| Depreciation & Amortization | $40 | $38 | $42 | $39 |
| EBITDA | -$514 | -$528 | $230 | -$493 |
| % Margin | -219.9% | -336.8% | 27.9% | -621.4% |